Table 4.
Comparison of clinical characteristics of male congenital hypogonadotropic hypogonadism patients in inheritance and de novo groups
| Clinical characteristic | Inheritance group (n=8) | De novo group (n=6) | P |
|---|---|---|---|
| Age at diagnosis (year), mean±s.d. | 17.8±4.5 | 17.0±2.1 | 0.68 |
| BMI (kg m−2), mean±s.d. | 24.2±5.8 | 22.2±4.2 | 0.50 |
| Incidence of cryptorchidism, n (%) | 2 (25.0) | 2 (33.3) | 0.99 |
| Incidence of short stature, n (%) | 0 (0) | 1 (16.7) | 0.42 |
| Incidence of skeletal anomalies, n (%) | 1 (12.5) | 2 (33.3) | 1.00 |
| Incidence of hearing loss, n (%) | 0 (0) | 1 (16.7) | 0.42 |
| Abnormal olfactory bulb and tract, n (%) | 4 (50.0) | 4 (66.7) | 0.62 |
| Baseline testis size (ml), mean±s.d. | 2.3±1.7 | 1.6±1.3 | 0.38 |
| Baseline LH (IU l−1), mean±s.d. | 0.5±0.4 | 0.2±0.1 | 0.07 |
| Baseline FSH (IU l−1), mean±s.d. | 1.0±0.5 | 0.5±0.2 | 0.03 |
| Baseline testosterone (nmol l−1), mean±s.d. | 1.3±1.0 | 0.9±0.3 | 0.22 |
BMI: body mass index; LH: luteinizing hormone; FSH: follicle-stimulating hormone; s.d.: standard deviation